TETLOW SHARON 4

4 · DICE Therapeutics, Inc. · Filed Sep 16, 2021

Form 4

Period: 2021-09-14

Director

Transactions

Award
Stock Option (right to buy)
2021-09-14+8,200→ 8,200 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (8,200 underlying)
Award
Stock Option (right to buy)
2021-09-14+8,261→ 8,261 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (8,261 underlying)
Award
Stock Option (right to buy)
2021-09-14+5,600→ 5,600 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (5,600 underlying)
Award
Stock Option (right to buy)
2021-09-14+12,096→ 12,096 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (12,096 underlying)

Holdings

Footnotes (5)

[F1]The number of shares of Common Stock reported in the Reporting Holder's Form 3 reflected the conversion of derivative securities based on the midpoint of the Issuer's initial public offering range of $16.00 per share. The number of shares of Common Stock reflected in this Form 4 reflects the adjusted number of shares issued based on the higher initial public offering price of $17.00 per share, and does not reflect a disposition of shares.
[F2]Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
[F3]The option vests as to 1/36th of the total shares monthly, beginning November 8, 2020, subject to the Reporting Holder's continued service to the Registrant.
[F4]The option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant.
[F5]The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant.

Documents

1 file